Sales & Marketing News | pharmaphorum

News

CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia

Biogen’s Skyclarys is on course to becoming the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU after it was recommended

News

MSD claims 2nd FDA approval for Welireg, in kidney cancer

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f

News

White House says 48 drugs are heading for Medicare rebates

The Biden administration has generated a list of 48 drugs whose prices were raised faster than inflation in the last quarter of this year and may be subject to the mandato

News

SCOTUS will rule on abortion pill access in landmark case

The Supreme Court of the US has said it will consider a lower court ruling that would restrict access to the abortion pill mifepristone and is considered to be tied to the

News

Eisai sets Leqembi price in Japan at a discount to US

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than

News

Final obstacles in front of Pfizer, Seagen merger fall

Pfizer is expecting to close its $43 billion acquisition of antibody-drug conjugate (ADC) pioneer Seagen tomorrow, after receiving all the required regulatory approvals fo

CHMP backs Biogen’s Skyclarys for Friedreich’s ataxia

MSD claims 2nd FDA approval for Welireg, in kidney cancer

White House says 48 drugs are heading for Medicare rebates

SCOTUS will rule on abortion pill access in landmark case

Eisai sets Leqembi price in Japan at a discount to US

Final obstacles in front of Pfizer, Seagen merger fall

GSK to quit Stevenage for new R&D site in Cambridge

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks